New model aims to end guesswork in IBD biologic treatment

NCT ID NCT07181525

Recruiting now Knowledge-focused Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

Inflammatory bowel disease (IBD) is a lifelong condition with no cure. Biologic drugs are a first-line treatment, but they fail in 30-50% of patients. This study will collect data from 200 IBD patients to build a predictive model using clinical features and machine learning. The goal is to create a tool that helps doctors choose the right biologic for each patient, improving outcomes and cutting unnecessary costs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: biologic drugs (anti-cytokine and anti-integrin antibodies)
What this could lead to: If successful, this could give doctors a reliable tool to predict which biologic will work for each IBD patient, saving time and money.
What could go wrong: This is an early-stage model-building study, not a treatment trial. The model may not be accurate enough for real-world use and needs further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMATORY BOWEL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMATORY BOWEL DISEASE

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.